|
|
Article: New drug for HIV patients.(HIV update)
- Article from:
- Medical Laboratory Observer
- Article date:
- May 1, 2007
CopyrightCOPYRIGHT 2007 Nelson Publishing. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Raltegravir shows promise in combating drug-resistant HIV, says an international study by Merck Research Laboratories in Pennsylvania published in The Lancet medical journal. This drug is one of a new class of drugs called integrase-inhibitors, which block an enzyme essential for HIV to replicate itself, according to news reports from the BBC. The study included 178 patients suffering from advanced HIV who were not responding to antiretroviral drugs they had ...
Related newspaper, magazine, and journal articles:
|
|
Article: Dr. Gary Gilliland Joins Merck Research Labs as ...
Health & Beauty Close-Up;
February 4, 2009 ;
700+ words
... ... and physician, has been named senior vice president of Merck Research Laboratories (MRL) and Oncology Franchise Head. Dr ... stature to the MRL team, said Peter S. Kim, president, Merck Research Laboratories. Gary's work and leadership have had major ...
|
|